NORWELL, Mass. — In an effort to address a critical workforce pipeline in medical science, the National Organization for Rare Disorders (NORD®) and the Rosenau Family Research Foundation officially launched a pioneering educational initiative designed to engage students and early-career scientists. Entitled the "Rare Research Launchpad: A Career Exploration Series in Rare Disease Research," the new offering is a free, self-paced online program created to introduce aspiring professionals to the specialized field of rare disease research and the diverse career trajectories available within it.
The initiative comes at a vital time for the biomedical sector. While individual rare conditions affect a relatively small number of people, collectively they represent a massive public health challenge. There are more than 10,000 known rare diseases affecting millions of individuals globally, yet only a fraction—approximately 600—currently have an FDA-approved treatment. By demystifying the research landscape early in a student’s academic or professional journey, the organizers hope to inspire a new wave of dedicated investigators to tackle these persistent unmet medical needs.
Available now through NORD’s RareEDU® online learning platform, the Rare Research Launchpad utilizes a curriculum grounded in real-world science. The program centers on two distinct conditions as primary case studies: cystic fibrosis and Krabbe disease. By examining these specific disorders, participants are introduced to the foundational science behind rare and genetic diseases, the complex journey of moving a discovery from an academic laboratory bench toward potential clinical therapies, and the multidisciplinary skills required to sustain such long-term investigations.
Funded by the Rosenau Family Research Foundation—a dedicated NORD Member Organization—and developed in close collaboration with researchers affiliated with the NORD® Rare Disease Centers of Excellence Network, the series offers a multifaceted learning experience. It intentionally blends rigorous scientific instruction with firsthand perspectives from academic researchers and families directly impacted by rare diseases, alongside practical career guidance. The initiative is tailored primarily for high school, undergraduate, and post-baccalaureate students interested in science and medicine who may otherwise have limited exposure to rare disease research. Additionally, it serves as a robust supplemental resource for graduate students and early-career trainees looking to navigate their professional options in biomedical science.
Program leaders emphasize that cultivating specialized talent is essential for keeping pace with modern technological breakthroughs. As the tools used to study genetic anomalies and engineer novel therapeutics continue to evolve rapidly, the scientific community must actively prepare the workforce that will shoulder this responsibility in the decades ahead.
“As technologies used to study rare and genetic diseases and develop new therapies continue to advance, we need to prepare the next generation of scientists who will carry this work forward,” said Rebecca Aune, MPA, Director of Education Programs at NORD. “Rare Research Launchpad gives students an early look at rare disease research and helps them understand the skills, experiences, and relationships that can lead to a career advancing science and improving the lives of millions of people with rare diseases.”
The choice of cystic fibrosis and Krabbe disease as the curriculum’s anchoring case studies was deliberate. Together, they provide participants with a comprehensive view of the spectrum of scientific challenges, biological mechanisms, and therapeutic opportunities found across the rare disease ecosystem. The two conditions expose learners to broader, foundational principles spanning genetics, molecular biology, neuroscience, and translational biomedical research. Furthermore, they illustrate how a synthesis of rigorous laboratory science, deep clinical expertise, and the lived experiences of patients and families can collectively inform research priorities and drive the creation of innovative treatments.
Critically, the two conditions also reflect different milestones along the modern therapeutic development landscape. Cystic fibrosis represents a historic success story of sustained scientific persistence; decades of dedicated research have culminated in multiple FDA-approved therapies, including precision medicines that target the underlying cellular mechanism of the disease. In contrast, Krabbe disease highlights the ongoing urgency of the field, as there is currently no FDA-approved therapy specifically indicated to treat the condition. By juxtaposing these distinct realities, the curriculum highlights both the extraordinary progress that rare disease research can achieve and the formidable scientific and therapeutic barriers that remain across the broader medical landscape.
For the Rosenau Family Research Foundation, the partnership represents a strategic investment in human capital and long-term scientific capability. Established in 2008 as a private family foundation, the organization has remained steadfastly focused on funding targeted research and advocating for individuals and families impacted by Krabbe disease and cystic fibrosis. Supporting educational initiatives like the Rare Research Launchpad allows the foundation to look beyond immediate laboratory projects and foster the intellectual infrastructure required for future breakthroughs.
“The Rosenau Family Research Foundation is focused on advancing research that can improve the lives of people affected by Krabbe disease and cystic fibrosis,” said Gabriel M. Cohn, MD, MBA, Executive Director and Medical Director of the Foundation. “Supporting NORD’s Rare Research Launchpad allows us to invest in future scientists while giving them a practical understanding of the research questions, career paths, and collaborations needed to advance treatments for the more than 10,000 known rare diseases of which only about 600 currently have an available treatment.”
Organizers have designed the Rare Research Launchpad as a scalable model, meaning the digital framework can expand over time. Future iterations could potentially incorporate additional rare disease research topics, broadening the scope of study and offering continuous pathways for student engagement and professional development.
The launch of the series underscores the ongoing evolution of NORD’s educational mission. Founded in 1983, NORD has grown into a leading independent, nonpartisan nonprofit organization dedicated to improving the health and well-being of the more than 30 million Americans living with rare diseases. Through collaborative networks encompassing over 350 disease-specific member patient organizations and 49 designated NORD Rare Disease Centers of Excellence—spanning more than 170 academic medical centers, research institutions, and children’s hospitals nationwide—the organization coordinates advocacy, clinical care improvements, and educational initiatives.
The Rare Research Launchpad is accessible immediately at no cost. Aspiring scientists, students, and educators interested in exploring the curriculum can find more information and enroll through the NORD RareEDU portal.
